Medical research

It’s ok if scientists disagree about antibiotic prescriptions

It is far better to find ways to communicate why evidence may be inconclusive than oversimplify medical science.

On numerous matters including food, health and the environment, experts are called upon to communicate the implications of scientific evidence for particular choices. It may be tempting to highlight simple messages from complex evidence. But as the recent controversy over advice on antibiotics shows, there is a risk of such messages backfiring when new evidence comes to light. So in these fractious times of “alternative facts”, how best can experts build trust with the public?

Evidence provided by science is often mixed, incomplete, changeable or conditional on context. Yet experts are expected to stick to narratives that highlight a consensus view. Simplifying the complex may be essential for public communication, but this is not the same as glossing over uncertainty or valid disagreements. It is far better to find ways to communicate why evidence may be inconclusive and why experts might reasonably make different judgements on the same question.

On antibiotics, it may be confusing to find experts giving conflicting assessments on whether or not people should “finish the course”. But far from representing post-truth, this disagreement suggests we must pay more attention to the matter of how to cope, despite the vagaries of expert consensus.

Fraying antibiotics consensus

Healthcare professionals have long stressed that people must not stop taking prescribed antibiotics when they feel better. Some experts recently questioned this conventional wisdom in the British Medical Journal, suggesting that the advice is not evidence-based and that it impedes conservation of antibiotics in light of bacterial resistance. Elsewhere, it is claimed that antibiotics are prescribed more out of fear and habit than on the basis of science.

But other experts have been critical, saying that the call to change established prescribing practice is dangerous as it is itself unsupported by sufficient evidence.

In this debate, many actually agree that it is worth reconsidering antibiotic duration, and that more clinical trials are needed to specify appropriate doses for different infections. Some consensus is emerging that shorter courses may sometimes be sensible – but more evidence is needed.

Chest physician Dr Prabhu and staff nurse Mala examine and evaluate a patient who defaulted on his anti-tuberculosis treatment (ATT) and is now a MDR (multi-drug resistant) TB (tuberculosis) suspect at the government hospital for chest diseases in Pondicherry, India, 2014. (Photo: CDC Global/Flickr)
Chest physician Dr Prabhu and staff nurse Mala examine and evaluate a patient who defaulted on his anti-tuberculosis treatment (ATT) and is now a MDR (multi-drug resistant) TB (tuberculosis) suspect at the government hospital for chest diseases in Pondicherry, India, 2014. (Photo: CDC Global/Flickr)

All agree, for example, that tuberculosis merits a longer course of antibiotics to cure the infection and possibly to prevent resistance. But for some common conditions, the recommended course has already been shortened to three days. Public health messages have subtly changed, with Public Health England telling people to take antibiotics “exactly as prescribed” rather than “completing the course”. Prescribers are asked to avoid unnecessarily lengthy durations.

So, calls to shorten antibiotic courses and gather more evidence are not new. But until recently, public discussion of the issue was rare.

Simple messages?

The real controversy provoked by the BMJ article is about what experts should tell the public. The authors suggest that primary care patients prescribed antibiotics for common bacterial infections could be advised to stop when they feel better. Many of their critics fear that such advice is too subjective, and people will be confused by experts disagreeing or departing from an established message. The Chief Medical Officer has reiterated that official advice is unchanged: follow what the doctor says.

The notion that experts must convey a simple message is based on the assumption that uncertainty creates anxiety, making people unsure of what to believe or how to act. Since being exposed to divergent views increases uncertainty, it seems to follow that experts must hew to a strict line. But health communication scholars suggest this is too simplistic as people manage and respond to uncertainty in different ways. Some may have good reasons to ignore debates among experts, relying instead on familiar routines that shape their beliefs and behaviour. Others may distrust markers of excessive confidence, finding open discussion more reassuring as it chimes with their own instincts about knowledge.

Even where some reduction in uncertainty is desirable, evidence is not a substitute for judgement. Doing scientific research to address complex matters often increases uncertainty as new evidence raises further questions. Clinical trials data generate their own dilemmas of assessment and interpretation for professionals.

In terms of antibiotic prescribing, one expert argues that trials are needed but clinical judgement will still be important. So evidence of one sort may be valuable but it must be put in context of other evidence and practical objectives. The same principle applies to most issues that experts investigate, from sex differences to the economic impact of Brexit.

Coping with uncertainty

In the case of antibiotic courses, it is unreasonable to expect that new evidence will automatically resolve current uncertainties. Science cannot meet such undue expectations. But this is only a problem in a culture where people expect prescriptions to be based on unshakeable evidence, and where experts cultivate that impression. On other issues such as climate change, where science is invoked to justify particular interventions to the public, we see the same pattern.

Tensions around the public role of science arise partly from the belief that the cultural credibility of expertise rests on communicating in terms of consensus. Whenever new knowledge seems to challenge current consensus, credibility becomes strained. We have recently highlighted how this diverts attention from more urgent practical challenges.

But if conflicting or inconclusive evidence from new science is taken to be the norm rather than the exception, uncertainty would not be a problem to fear or eliminate. Similar points have been made in relation to health communication, where evidence provided by new technologies of screening and testing is often ambiguous.

Promising consensus as derived from scientific evidence is a perilous principle on which to found meaningful engagement between experts and the public. We are better off trying to facilitate improved ways of appraising and coping with entirely normal uncertainties and reasons for disagreement.

Sujatha Raman,Associate Professor in Science and Technology Studies, University of Nottingham andWarren Pearce,Faculty Fellow (iHuman), University of Sheffield.

This article was first published on The Conversation.

Support our journalism by paying for Scroll+ here. We welcome your comments at
Sponsored Content BY 

Some of the most significant innovations in automotive history made their debut in this iconic automobile

The latest version features India's first BS VI norms-compliant engine and a host of 'intelligent' features.

The S-Class, also known as Sonderklasse or special class, represents Mercedes Benz’ top-of-the-line sedan line up. Over the decades, this line of luxury vehicles has brought significant automotive technologies to the mainstream, with several firsts to its credit and has often been called the best car in the world. It’s in the S-Class that the first electronic ESP and ABS anti-lock braking system made their debut in the 20th century.

Twenty first-century driver assistance technologies which predict driver-behaviour and the vehicle’s course in order to take preventive safety measures are also now a staple of the S-Class. In the latest 2018 S-Class, the S 350 d, a 360-degree network of cameras, radars and other sensors communicate with each other for an ‘intelligent’ driving experience.

The new S-Class systems are built on Mercedes Benz’s cutting-edge radar-based driving assistance features, and also make use of map and navigation data to calculate driving behaviour. In cities and on other crowded roads, the Active Distance Assist DISTRONIC helps maintain the distance between car and the vehicle in front during speeds of up to 210 kmph. In the same speed range, Active Steering Assist helps the driver stay in the centre of the lane on stretches of straight road and on slight bends. Blind Spot Assist, meanwhile, makes up for human limitations by indicating vehicles present in the blind spot during a lane change. The new S-Class also communicates with other cars equipped with the Car-to-X communication system about dicey road conditions and low visibility due to fog, rain, accidents etc. en route.

The new S-Class can even automatically engage the emergency system when the driver is unable to raise an alarm. Active Emergency Stop Assist brings the car to a stop if it detects sustained periods of inactivity from the driver when Active Steering Assist is switched on. If the driver doesn’t respond to repeated visual and audible prompts, it automatically activates the emergency call system and unlocks the car to provide access to first responders.

The new Mercedes-Benz S 350 d in India features another notable innovation – the country’s first BS VI norms-compliant car engine, in accordance with government regulations to control vehicular pollution. Debuting two years before the BS VI deadline of 2020, the S 350 d engine also remains compatible with the current BS IV fuels.

The S 350 d is an intelligent car made in India, for Indian roads - in the Mercedes Benz S-Class tradition. See the video below to know what drives the S-Class series by Mercedes Benz.

To know more about the 2018 S-Class, click here.


This article was produced by the Scroll marketing team on behalf of Mercedes Benz and not by the Scroll editorial team.